PathAI Gets FDA Pathology Clearance
PathAI’s AISight® Dx platform has received FDA 510(k) clearance for primary diagnosis in digital pathology. This marks a significant step for AI in routine clinical use, moving beyond triage or secondary analysis to become a regulated diagnostic tool for pathologists. It's a key indicator of AI's expanding role across all of diagnostics, not just radiology.
This clearance includes a Predetermined Change Control Plan (PCCP), a newer FDA framework that allows PathAI to update its platform for new scanners, file formats, and browsers without new 510(k) submissions. This regulatory agility is a significant competitive advantage, enabling faster integration and innovation compared to traditional medical device software pathways. The approval positions PathAI in a digital pathology market projected to grow from over $1.5 billion in 2025 to more than $3.2 billion by 2031, with a compound annual growth rate around 9.9%. North America currently dominates the market, holding nearly 48% of the revenue share in 2025, driven by high adoption of digital imaging and the presence of key industry players. PathAI's clearance is part of a much larger trend; the FDA has authorized over 1,200 medical devices with AI/ML capabilities as of mid-2025, the vast majority through the 510(k) pathway. In the pathology sub-specialty, its key competitor is Paige, which gained the first FDA approval for an AI-based cancer diagnostic tool for prostate biopsies in 2021. This type of cloud-native technology that enables remote, real-time collaboration is a critical enabler for the broader shift of diagnostic services out of traditional hospital settings. As health systems build out their freestanding imaging and diagnostic networks, platforms that allow specialists to connect and review cases from any location become essential infrastructure. The outpatient imaging boom is heavily driven by reimbursement changes from both CMS and commercial payers aiming to cut costs. Policies like the Bipartisan Budget Act of 2015 reduced payments for services at off-campus hospital outpatient departments (HOPDs), directly incentivizing the move to lower-cost freestanding facilities. In response, hospital systems are aggressively expanding their outpatient footprint through acquisitions and joint ventures with existing imaging centers. This strategy aims to prevent patient leakage and capture volume that is being actively steered away from the main hospital campus by payers. This pressure has fueled significant consolidation among outpatient providers, with large, well-capitalized operators like RadNet and private equity firms acquiring smaller, struggling centers. For mobile imaging providers, this means navigating a landscape of fewer independent centers and more extensive, integrated health system networks.
